ETV7 is a transcriptional regulator that functions as both a context-dependent repressor and activator in distinct biological processes. As a member of the ETS family, ETV7 binds specific DNA sequences and regulates transcription through chr6 remodeling mechanisms 1. In immune contexts, ETV7 serves a critical repressive function. It acts as a central transcriptional node that drives CD8+ T cell differentiation from memory toward terminal exhaustion by binding to both memory and exhaustion genes, thereby limiting antiviral and antitumor immunity 2. However, when LAG-3 and PD-1 are simultaneously blocked, ETV7 co-expression with other factors (PRDM1, BATF, TOX) enables enhanced CD8+ cytotoxicity despite exhaustion persistence 3. In cancer contexts, ETV7 functions as an oncoprotein. In breast cancer, ETV7 represses TNFRSF1A (TNFR1) through direct binding and competitive interaction with STAT3, thereby reducing inflammatory NF-κB signaling 1. ETV7 also represses DNAJC15, promoting doxorubicin resistance through enhanced drug efflux 4. In colorectal cancer, ETV7 activates IFIT3 transcription to promote proliferation and migration 5. ETV7 expression is negatively correlated with progression-free survival and checkpoint blockade responsiveness 2. In hematopoiesis, ETV7 accelerates Pten-deficiency-driven leukemogenesis 6 and regulates red blood cell development via cholesterol synthesis 7. ETV7 represents a promising therapeutic target for cancer immunotherapy and chemoresistance 2.